English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12190/12972 (94%)
Visitors : 983593 Online Users : 545
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
分子與基因醫學研究所
生技與藥物研究所
生醫工程與奈米醫學研究所
免疫醫學研究中心
神經及精神醫學研究中心
細胞及系統醫學研究所
感染症與疫苗研究所
群體健康科學研究所
癌症研究所
國家環境醫學研究所
國家蚊媒傳染病防治研究中心
高齡醫學暨健康福祉研究中心
論壇
生醫資源中心
研究生培育合作學程
核心儀器設施中心
病理核心實驗室
實驗動物中心
行政管理部門
圖書館
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
國家衛生研究院 NHRI
>
Items for Author
Loading...
Category
Loading community tree, please wait....
Year
Loading year class tree, please wait....
Items for Author "Muro, K"
Return to Browse by Author
Showing 13 items.
Collection
Date
Title
Relation
Bitstream
[陳立宗] 期刊論文
2022-01
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
-
[陳立宗] 期刊論文
2021-07
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
-
[陳立宗] 期刊論文
2020-05
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
-
[陳立宗] 會議論文/會議摘要
2020-02
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data
-
[陳立宗] 期刊論文
2020-01
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
-
[陳立宗] 期刊論文
2019-03
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
-
[陳立宗] 會議論文/會議摘要
2019-02
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
-
[陳立宗] 期刊論文
2019-01
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
-
[陳立宗] 期刊論文
2019-01
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
-
[陳立宗] 期刊論文
2018-01
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
-
[陳立宗] 期刊論文
2017-12
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
-
[陳立宗] 會議論文/會議摘要
2017-09
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
-
[陳立宗] 會議論文/會議摘要
2017-02
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
-
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback